CN108884142A - 用于癌症治疗的工程化trail - Google Patents

用于癌症治疗的工程化trail Download PDF

Info

Publication number
CN108884142A
CN108884142A CN201780016988.2A CN201780016988A CN108884142A CN 108884142 A CN108884142 A CN 108884142A CN 201780016988 A CN201780016988 A CN 201780016988A CN 108884142 A CN108884142 A CN 108884142A
Authority
CN
China
Prior art keywords
ser
gly
leu
trail
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780016988.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·H·C·马卡恩托尼奥
S·L·萨辛斯基
B·M·肖伯尔
E·M·塔姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of CN108884142A publication Critical patent/CN108884142A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780016988.2A 2016-03-16 2017-03-16 用于癌症治疗的工程化trail Pending CN108884142A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662309352P 2016-03-16 2016-03-16
US62/309,352 2016-03-16
US201662323501P 2016-04-15 2016-04-15
US62/323,501 2016-04-15
US201762445556P 2017-01-12 2017-01-12
US62/445,556 2017-01-12
PCT/US2017/022789 WO2017161173A1 (en) 2016-03-16 2017-03-16 Engineered trail for cancer therapy

Publications (1)

Publication Number Publication Date
CN108884142A true CN108884142A (zh) 2018-11-23

Family

ID=58413224

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780016988.2A Pending CN108884142A (zh) 2016-03-16 2017-03-16 用于癌症治疗的工程化trail

Country Status (10)

Country Link
US (1) US20190077870A1 (enExample)
EP (1) EP3430034A1 (enExample)
JP (1) JP2019518713A (enExample)
KR (1) KR20180127407A (enExample)
CN (1) CN108884142A (enExample)
AU (1) AU2017234679A1 (enExample)
CA (1) CA3017622A1 (enExample)
IL (1) IL261267A (enExample)
MX (1) MX2018011219A (enExample)
WO (1) WO2017161173A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026181A (zh) * 2015-10-22 2018-05-11 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190017804A (ko) * 2016-06-13 2019-02-20 메리맥 파마슈티컬즈, 인크. 환자를 선별하고 trail-기반 치료제 또는 사멸 수용체 효능제로 치료하는 방법
CN109125709B (zh) * 2018-08-23 2021-10-22 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂
KR102764218B1 (ko) * 2020-10-13 2025-02-11 신동준 반려견의 항암용 재조합 단백질 및 이를 포함하는 반려견을 위한 항암용 조성물

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0220296A (ja) * 1988-07-07 1990-01-23 Tanpaku Kogaku Kenkyusho:Kk 変異ヒト腫傷壊死因子
CN1370232A (zh) * 1999-06-28 2002-09-18 杰南技术公司 利用二价金属离子制备Apo－2配体的方法
CN1926152A (zh) * 2003-12-05 2007-03-07 格罗宁根大学 改进的细胞因子设计
WO2010141329A1 (en) * 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
CN102388062A (zh) * 2007-12-17 2012-03-21 私人基金基因组调控中心(Crg) 用于治疗癌症的trail变体
WO2012085891A2 (en) * 2010-12-24 2012-06-28 Rijksuniversiteit Groningen Tnf family ligand variants
WO2012130471A1 (en) * 2011-04-01 2012-10-04 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
WO2015164588A1 (en) * 2014-04-23 2015-10-29 Abbvie, Inc. Single-chain trail-receptor agonist proteins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
PL2310509T3 (pl) * 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2011139681A1 (en) 2010-04-26 2011-11-10 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
CN111592601A (zh) * 2011-07-06 2020-08-28 江苏靶标生物医药研究所有限公司 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用
US10428149B2 (en) * 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0220296A (ja) * 1988-07-07 1990-01-23 Tanpaku Kogaku Kenkyusho:Kk 変異ヒト腫傷壊死因子
CN1370232A (zh) * 1999-06-28 2002-09-18 杰南技术公司 利用二价金属离子制备Apo－2配体的方法
CN1926152A (zh) * 2003-12-05 2007-03-07 格罗宁根大学 改进的细胞因子设计
CN102388062A (zh) * 2007-12-17 2012-03-21 私人基金基因组调控中心(Crg) 用于治疗癌症的trail变体
WO2010141329A1 (en) * 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
WO2012085891A2 (en) * 2010-12-24 2012-06-28 Rijksuniversiteit Groningen Tnf family ligand variants
WO2012130471A1 (en) * 2011-04-01 2012-10-04 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
WO2015164588A1 (en) * 2014-04-23 2015-10-29 Abbvie, Inc. Single-chain trail-receptor agonist proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALMER M VAN DER SLOOT等: "Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor", 《PNAS》 *
FANG FANG等: "Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand", 《ACTA PHARMACOLOGICA SINICA》 *
ROBERT F. KELLEY等: "Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *
VICENTE TUR等: "DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *
关良: "重组人TRAIL及突变体的原核表达和抗肿瘤生物活性研究", 《中国博士学位论文全文数据库（电子期刊）》 *
韩蕾等: "重组人肿瘤坏死因子凋亡诱导配体突变体稳定性研究", 《中国药学杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026181A (zh) * 2015-10-22 2018-05-11 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
CN108026181B (zh) * 2015-10-22 2021-07-02 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用

Also Published As

Publication number Publication date
IL261267A (en) 2018-10-31
US20190077870A1 (en) 2019-03-14
WO2017161173A1 (en) 2017-09-21
CA3017622A1 (en) 2017-09-21
EP3430034A1 (en) 2019-01-23
MX2018011219A (es) 2019-01-10
AU2017234679A1 (en) 2018-08-30
KR20180127407A (ko) 2018-11-28
JP2019518713A (ja) 2019-07-04

Similar Documents

Publication Publication Date Title
AU2020201323B2 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
KR102427192B1 (ko) 항-인간 4-1bb 항체 및 그의 용도
US11377477B2 (en) PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
KR102426765B1 (ko) Cd137에 대한 신규한 이중특이성 폴리펩타이드
JP7148539B2 (ja) 免疫抱合体
JP6944369B2 (ja) Ｔ細胞活性化二重特異性抗原結合分子ｃｄ３ ａｂｄ葉酸受容体１（ｆｏｌｒ１）及びｐｄ−１軸結合アンタゴニストの併用療法
TW202227494A (zh) 多特異性免疫靶向分子及其用途
JP2021129564A (ja) 共通軽鎖および使用方法
CN112789294A (zh) 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
CN112512581A (zh) 针对cldn18.2和cd3的抗体构建体
CN111741979A (zh) 包含4-1BBL的Her2靶向性抗原结合分子
JP2021528988A (ja) 新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
KR20230029621A (ko) T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법
CN110087682A (zh) 用靶向性4-1bb(cd137)激动剂的组合疗法
CN116333138A (zh) Pd-1结合分子和其使用方法
CN108884142A (zh) 用于癌症治疗的工程化trail
US20240209106A1 (en) Anti-cd137 antibodies and methods of use
JP2024012336A (ja) トランスサイレチン免疫グロブリン融合物
CN111465618A (zh) 双特异性cd16-结合分子及其在疾病治疗中的用途
CN115279403A (zh) Cd137结合分子及其用途
US20240209113A1 (en) Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
CN118434768A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
HK40004686B (en) Novel bispecific polypeptides against cd137
HK1236976B (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181123